Research on any compound tends to move through recognizable stages: cell-culture (in-vitro) studies test whether a mechanism is plausible at all; animal (in-vivo) studies test whether that mechanism produces an effect in a living system; and human clinical trials test whether the effect holds in people, under controlled conditions. Each stage answers a narrower, more specific question than the one before it — and each is more expensive, slower, and harder to run, which is exactly why there’s far more in-vitro and animal literature in existence than human trial data for most research compounds.

This hierarchy is exactly why the Signal Library’s disclaimers distinguish “laboratory and animal-model research” from clinical evidence. BPC-157, for instance, has an extensive animal-model literature spanning decades, but that’s a different evidentiary tier than tesamorelin‘s published human Phase 3 trials, covered in the previous lesson. Neither tier is “wrong” — they’re answering different questions, at different stages of a compound’s research history. Recognizing which tier you’re reading is the whole skill.